SCHEMBL2886428

SCHEMBL2886428

CCOC(=O)c1c(Cl)c(Cl)n(CCC(C)C)c1CBr

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
ALDH1A1 P00352 7/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
MAPT P10636 4/20 0.33
LMNA P02545 2/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 4/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
CASP1 P29466 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GAA P10253 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2883762 0.84 MAPT (0.42) KMT2AL3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL17817951 0.69 KDM4E (0.43) L3MBTL1ALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL522852 0.65 ALDH1A1 (0.54) KMT2AALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL9974832 0.64 KDM4E (0.49) KMT2AL3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL9974823 0.64 MAPT (0.53) KMT2AL3MBTL1ALDH1A1SMN1; SMN2MAPT
SCHEMBL2881247 0.63 KMT2A (0.45) KMT2AALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL5331916 0.63 ALDH1A1 (0.52) KMT2AALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL5514070 0.61 CNR2 (0.42) KMT2AL3MBTL1ALDH1A1MAPTLMNA
SCHEMBL7203276 0.61 ALDH1A1 (0.50) KMT2AALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL2880809 0.61 TSHR (0.50) KMT2AL3MBTL1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 KMT2A 1354/4885L3MBTL1 3076/4885CYP4F2 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.